The complex of pharmaceutical, chemical and food crafts which is called “Shahid Modarres” was designed in the 1360s and some units such as "sorbitol", "metallic Stearate" and "Citrate" were founded in it. It has not achieved its strategic objectives yet and the units also did not last long and were closed. Now after some years, a question is raised: regarding to the production and consumption conditions in Iran’s pharmaceutical market, the network connections between pharmaceutical active ingredients and other influencing factors, in which active ingredients investments are probably more profitable?
According to various criteria have been described in the second chapter of the study, investment in the production of the beneath active ingredients can be profitable potentially, although the decision to investment requires analyzing detailed cost-benefit for each of the mentioned items: Amoxicillin, Ampicillin, Cephalexin, Cefixime, Ceftriaxone, Cefazolin, Ciprofloxacin, Methocarbamol, Sulfamethoxazole and Atenolol.
One of the active units of Shahid Modarres’ complex was sorbitol unit that was stopped in the early of 1380s, so in this study, a cost-benefit analysis on the restarting of sorbitol was done. The main results are: first, the profitability and competitiveness of this unit is dependent on the scale of production and focus on the Iranian market can not provide this scale. Second, focus on the dextrose’s production as main ingredient of sorbitol, is especially important in sorbitol profitability. Third, exchange rate is more crucial in the price of imported products in comparison with produced ones.